NASDAQ:APRE

Aprea Therapeutics Q1 2026 Earnings Results & Report

Aprea Therapeutics logo
$0.46 +0.01 (+2.60%)
Closing price 04:00 PM Eastern
Extended Trading
$0.46 -0.01 (-1.91%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$0.22 versus the -$0.23 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Aprea Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Q1 2026 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.22 per share for Q1 2026, beating the consensus estimate of -$0.23. The report was announced on Wednesday, May 13, 2026.

Aprea Therapeutics Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile